AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 8.52 |
Market Cap | 1.37B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.18 |
PE Ratio (ttm) | -3.91 |
Forward PE | n/a |
Analyst | Buy |
Ask | 8.63 |
Volume | 2,341,192 |
Avg. Volume (20D) | 5,293,659 |
Open | 8.77 |
Previous Close | 8.61 |
Day's Range | 8.40 - 8.79 |
52-Week Range | 3.53 - 23.86 |
Beta | undefined |
About NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria...
Analyst Forecast
According to 6 analyst ratings, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 117.00% from the latest price.
Next Earnings Release
Analysts project revenue of $176.05M, reflecting a -39.57% YoY shrinking and earnings per share of -0.29, making a -80.27% decrease YoY.
1 month ago · seekingalpha.com
Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript)Novavax, Inc. (NASDAQ:NVAX ) Jefferies London Healthcare Results Conference November 20, 2024 6:00 AM ET Company Participants Jim Kelly - Executive Vice President, Chief Financial Officer and Treasure...
2 months ago · seekingalpha.com
Novavax Q3 Earnings Disappoint, But A Turnaround May Be UnderwayNovavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial c...